Diabetic Retinopathy / Vision Loss Secondary to Type 2 Diabetes Mellitus

Yes. Under 38 CFR § 3.310(a), any disability proximately caused or chronically worsened by a service-connected condition is itself service-connected. Diabetic Retinopathy / Vision Loss is a documented secondary pairing for Type 2 Diabetes Mellitus with strong medical evidence. A nexus letter from a qualified physician linking the two conditions is the most reliable way to establish this connection.

The gold standard is a private nexus opinion stating — to at least a 50% probability ("at least as likely as not") — that the secondary condition was caused or aggravated by the primary service-connected condition. Peer-reviewed medical literature supporting the physiological mechanism strengthens the nexus. Treatment records documenting the onset or worsening of the secondary condition in temporal relation to the primary are supporting evidence.

The VA rates Diabetic Retinopathy / Vision Loss separately under its own 38 CFR Part 4 diagnostic code, then combines it with Type 2 Diabetes Mellitus and all other service-connected ratings using the combined ratings formula under § 4.25. The formula applies the whole-person concept: a 50% combined existing rating plus a new 30% rating yields 65% (rounded to 70%), not 80%.

38 CFR § 3.310(a) states: "Disability which is proximately due to or the result of a service-connected disease or injury shall be service connected." The aggravation variant under § 3.310(b) applies where the primary condition permanently worsens a pre-existing disability beyond its natural progression. Both standards require a showing of nexus — a medical or scientific link between the primary condition and the secondary.

The medical evidence supporting Diabetic Retinopathy / Vision Loss as secondary to Type 2 Diabetes Mellitus is rated strong. Diabetic retinopathy (DR) is a microangiopathic complication of diabetes resulting from hyperglycemia-induced damage to retinal pericytes and endothelial cells. Loss of pericytes allows capillary microaneurysm formation, hemorrhage, exudate deposition, and macular edema. Neovascularization (proliferative DR) from retinal ischemia and VEGF release risks vitreous hemorrhage and tractional retinal detachment. DR is the leading cause of new blindness in working-age adults in developed countries. Approximately 80% of Type 2 diabetic patients develop some degree of DR after 20 years of disease. The VA rates DR under the Eye section based on visual acuity loss and scotoma.

The VA will not solicit nexus evidence on your behalf for secondary claims. In practice, a written nexus opinion from a private physician or independent medical examiner is essential — the VA's Compensation & Pension (C&P) examiner is not required to produce a favorable nexus opinion, and the VA has discretion to weigh competing opinions. Submitting a private nexus letter at the time of filing is the most reliable strategy.